Does the CYP1A2 rs762551 AC genotype mean caffeine can interfere with sleep later in the day?

Genetic and pharmacokinetic profile

• The CYP1A2 gene encodes the primary hepatic enzyme responsible for the clearance of caffeine. Within this gene, the rs762551 single-nucleotide polymorphism significantly dictates enzymatic inducibility and metabolic capacity.
• Individuals with the heterozygous rs762551 AC genotype possess an intermediate caffeine metabolizer phenotype. While homozygous AA carriers clear caffeine rapidly and CC carriers clear it very slowly, AC individuals exhibit an intermediate clearance rate that sits between these two extremes.
• This intermediate metabolism extends caffeine's typical half-life from the standard 3 to 5 hours seen in rapid metabolizers to a prolonged 6 to 9+ hours. Consequently, even a moderate mid-afternoon dose leaves substantial active caffeine circulating in the bloodstream and brain at bedtime.

Mechanistic impact on sleep

• Sustained levels of circulating caffeine act as a competitive antagonist at adenosine A1 and A2A receptors within wake-promoting circuits.
• By physically blocking these receptors, caffeine prevents endogenous adenosine—which accumulates naturally during wakefulness—from binding and delivering its inhibitory, sleep-promoting signals.
• This direct blockade of the homeostatic sleep drive blunts the signaling required for sleep transition, resulting in prolonged sleep onset latency, reduced slow-wave sleep intensity, and sleep fragmentation.

Bottom line

• For individuals with the CYP1A2 rs762551 AC genotype, intermediate caffeine clearance means mid-to-late-day caffeine consumption results in elevated bedtime caffeine levels that block adenosine receptors, directly disrupting nocturnal sleep pressure and delaying sleep onset.